Abstract: A process for preparing amorphous paroxetine hydrochloride or sertraline hydrochloride is provided, which comprises preparing a solution in which paroxetine hydrochloride or sertraline hydrochloride and a water-soluble polymer are dissolved in a co-solvent of a volatile organic solvent and water. Said solution is dried to obtain a composition comprising amorphous paroxetine hydrochloride or sertraline hydrochloride and the water-soluble matrix.

Abstract: A composition for transdermal and dermal administration of interferon-&agr; is described. The composition is comprised of lipid vesicles including a fatty acylated amino acid and an oil-in-water emulsion. Interferon-&agr; is entrapped in the vesicles.

Abstract: A pharmaceutical compound and a process for making the compound is provided where the compound includes a therapeutic agent, a spacer and a galactose, the spacer being covalently linked to the therapeutic agent at a first site on the spacer and covalently linked to the galactose by an ether bond at a second site on the spacer to form a conjugate. The conjugate may be used to treat a subject suffering from a medical condition, so as to reduce the side effects associated with the therapeutic agent by administering an effective dose of the conjugate to the subject so that the side effects in the subject are less then they would have been with the unconjugated therapeutic agent.

Abstract: Immune response modifier compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines—are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Abstract: Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent.

Abstract: A preservative system comprising iodopropynyl butyl carbamate and phenoxyethanol at a weight ratio of iodopropynyl butyl carbamate to phenoxyethanol within the range of about 1:90 to about 1:400 shows a broad anti-microbial effect and can permit use of the preservative system at a low level in end use products such as personal care products.

Abstract: Disclosed is a deodorizer composition comprising magnesium and calcium phosphate compounds, capable of effectively removing various malodorous components from the atmosphere.

Abstract: A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.

Abstract: A pharmaceutical sublingual solid dosage form comprising a morphine salt together with excipients including a saccharide, a binder and a disintegrant. A method of manufacturing the dosage form is also described, together with packaging suitable for long term storage of the dosage form.

Abstract: The present invention provides an osmotic device containing controlled release venlafaxine in the core in combination with an anti-psychotic agent in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One embodiment of the osmotic device includes an external coat that has been spray-coated rather compression-coated onto the device. The device with spray-coated external core is smaller and easier to swallow than the similar device having a compression-coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.

Abstract: A method of preparing a rapid acting bait composition which is water based and contains a water-sensitive insecticide as an active ingredient is described. The composition is easily applied into cracks and crevices and voids or other pest harborage areas to rapidly kill insect pests, particularly cockroaches. A kit is also described for preparation of the composition.

Abstract: A method for treating a patient suffering from a renal failure progressed to a stage at which an initiation of a dialysis therapy is required, comprising combining a peritoneal dialysis and an administration of a spherical carbon, is disclosed.

Abstract: The object of the present invention is to provide a pharmaceutical composition optimized for the administration of a drug, particularly a drug which is only sparingly soluble in water, by way of inhalation. The present invention is a fat emulsion for inhalational administration, or a lyophilized composition thereof, which is an o/w fat emulsion comprising fat emulsion particles essentially composed of an oil component, an emulsifying agent and a drug as dispersed in water, characterized in that the average particle diameter of said fat emulsion particles lies within the range of 5˜100 nm. With the aid of a suitable inhaler, the inhalant of the invention readily yields a mist of aerosol particles fine enough to reach the alveolus; the inhalant is well amenable to size control of the aerosol particles.

Abstract: A human scent control device including a collapsible conical housing having a bottom end of larger circumference than the top end and having a structural support means consisting of several rigid rings attached within said housing. An exhaust fan motor is affixed within the top of the housing for drawing human scent through one or more filters retained by the rings. The device is provided velcro straps to attach the device to a tree or stand to suspending the conical housing above the area occupied by a human.

Abstract: A method for the preparation of compositions, preferably pharmaceutical compositions, in form of expanded, mechanically stable, lamellar, porous, sponge-like or foam structures out of solutions and dispersions results in a favored pharmaceutical product. This method comprises the steps of a) preparing a solution or a homogeneous dispersion of a liquid and a compound selected from the group consisting of one or more pharmaceutically active compounds, one or more pharmaceutically suitable excipients, and mixtures thereof, followed by b) the expansion of the solution or the homogeneous dispersion without boiling.

Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material (4) in the powder has been found to give an increased respirable fraction of the active material.

Abstract: Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.

Abstract: A composition containing enhanced colloidal oatmeal which utilizes other avena sativa ingredients to neutralize the discomfort, irritation and inflammation of the skin, as well as maintaining normal skin, and can be used to treat many types of discomforts, including itching; due to poison ivy, oak and sumac, insect bites, sunburn, chicken pox, hives, prickly heat, chafing, and the like while maintaining the normal pH of the skin.

Abstract: The invention provides a method for inhibiting the binding of a biguanide disinfectant in aqueous solution to a poly(ethylene) solid in contact with said solution comprising providing in said solution an amount of cyclodextrin sufficient to inhibit binding of the biguanide disinfectant to the poly(ethylene) solid.

Abstract: An antibacterial, antifungal or antialgal article includes an antibacterial, antifungal or antialgal component, for example, silver and copper, an alloy thereof or a compound thereof diffused from a surface into the inside of the surface portion of an article, for example, a metal, glass or ceramic article.